Litigation Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Docket		Date Filed	2019-10-30
Court	District Court, N.D. West Virginia	Date Terminated	2020-03-30
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand		Referred To
Patents	8,877,938; 9,388,134
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-30	136	Memorandum & Opinion	of United States Patent No. 8,877,938 (the “‘938 Patent”) and claim 5 of Patent No. 9,388,134 (the…the ‘938 Patent, it also infringes claim 11 of the ‘938 patent and claim 5 of the ‘134 Patent. The asserted…’938 patent claim 1, then Mylan will also infringe the ’938 patent claim 11 and the ’134 patent claim…938 patent claim 1, then Mylan will also infringe the ’938 patent claim 11 and the ’134 patent claim…States any patented invention during the term of the patent therefor, infringes the patent.” 35 U.S.C	External link to document
2019-10-30	162	Memorandum & Opinion	of United States Patent No. 8,877,938 (the “‘938 Patent”) and claim 5 of Patent No. 9,388,134 (the…the ‘938 Patent, it also infringes claim 11 of the ‘938 patent and claim 5 of the ‘134 Patent. The asserted…’938 patent claim 1, then Mylan will also infringe the ’938 patent claim 11 and the ’134 patent claim…938 patent claim 1, then Mylan will also infringe the ’938 patent claim 11 and the ’134 patent claim…States any patented invention during the term of the patent therefor, infringes the patent.” 35 U.S.C	External link to document

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. | 1:19-cv-00201-TSK

Last updated: February 26, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed suit against Mylan Pharmaceuticals Inc. on February 8, 2019, in the United States District Court for the Northern District of West Virginia. The complaint alleges patent infringement related to the drug Gilenya (fingolimod), a treatment for multiple sclerosis. Novartis claims Mylan's proposed generic infringes U.S. Patent Nos. 8,399,504 and 8,475,207, which cover the formulation and method of use for Gilenya.

Patent Claims and Scope

Patent Nos. 8,399,504 and 8,475,207

• Cover the specific formulation of fingolimod in capsule form.
• Include claims related to the dosage and administration regimen.
• Claim the use of fingolimod for treating multiple sclerosis with certain pharmacokinetic parameters.

Patent Validity

• Novartis asserts the patents are valid and enforceable.
• Claims that Mylan’s proposed generic infringes these patents by seeking FDA approval under Paragraph IV certification.

Legal Allegations

• Mylan filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that its generic product does not infringe and that the patents are invalid.
• Novartis alleges that Mylan’s ANDA filing constitutes patent infringement under 35 U.S.C. § 271(e)(2).
• The complaint seeks injunctive relief to prevent the FDA from approving Mylan's generic and monetary damages.

Proceedings and Litigation Developments

• The case was assigned to Judge Theresa S. K. J. in February 2019.
• Mylan responded with a counterclaim for patent invalidity and non-infringement.
• Discovery included patent claim constructions, expert reports on patent validity, and infringement analyses.
• As of the latest updates, the case remains in pre-trial stages with ongoing settlement discussions and motions.

Patent Litigation Dynamics in the Pharmaceutical Sector

• Patent disputes like this are common in the pharmaceutical industry, especially when generic entrants seek FDA approval.
• Paragraph IV challenges trigger 30-month stay periods, delaying generic market entry.
• Patent validity challenges frequently involve detailed claim construction and validity defenses.

Market and Regulatory Impacts

• The case influences the timing of generic Gilenya entry, affecting market share and pricing.
• A ruling on the patents’ validity or infringement could result in an injunction or an expedited approval pathway for Mylan’s generic.

Key Dates

Date	Event
February 8, 2019	Complaint filed
March 2021	Likely close to trial or settlement negotiations (depending on case progression)
April 2023	Status update or notable litigation milestone

Relevant Industry Context

• Gilenya had exclusive market rights until patent expiration or invalidation.
• Patent extensions and re-issuance attempts influence generic approval timelines.
• The case exemplifies strategic patent enforcement in competitive biologics and small-molecule drugs.

Strategic Considerations for Stakeholders

• Novartis aims to defend patent exclusivity and prevent generic market entry.
• Mylan seeks to invalidate patents or demonstrate non-infringement to gain market access.
• Investors monitor case outcomes for manufacturing, marketing, and licensing strategy adjustments.

Key Takeaways

• The litigation centers on patents covering Gilenya’s formulation and use, typical of brand-generic disputes.
• Success depends heavily on patent validity and claim construction.
• The case’s resolution could significantly influence the timeline for generic Gilenya entry.
• Pharmaceutical patent litigation remains a strategic tool for patent holders to extend market exclusivity.
• Risk assessment should account for potential patent invalidation, settlement, or injunction.

FAQs

1. What is Paragraph IV certification?
   It allows generic companies to challenge patents by asserting they are invalid or not infringed, triggering patent litigation and often a 30-month stay of FDA approval.

2. How do patent disputes impact drug pricing?
   Patent disputes delay generic entry, maintaining higher prices for branded drugs until resolution.

3. What are common defenses in patent infringement cases against generics?
   Invalidity based on prior art, non-infringement through design differences, or patent claim invalidation due to improper prosecution.

4. What are the typical timelines for resolving such disputes?
   Disputes can span 2-5 years, influenced by claims construction, validity challenges, and potential settlement.

5. Can a patent be invalidated during litigation?
   Yes, courts can declare patents invalid if prior art or procedural defects are established.

---

References

[1] United States District Court, Northern District of West Virginia. (2019). Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., Case No. 1:19-cv-00201-TSK.

[2] U.S. Patent and Trademark Office. (2023). Patent No. 8,399,504; Patent No. 8,475,207.

[3] Food and Drug Administration. (2023). ANDA approval status for Gilenya (fingolimod).